LukeTNordquistMD

Oncology • Omaha, NE

Genitourinary Oncology, Hematologic Oncology

CEO and Medical Director, Urology Cancer Center and GU Research Network

Join to view full profile

Dr. Nordquist is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Nordquist's full profile

Already have an account?

Office
17607 Gold Plaza
Omaha, NE 68130
Fax+1 402-991-8469
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
University of South Florida MorsaniResidency, Internal Medicine, 1998 - 2001
Creighton University School of MedicineClass of 1998

Certifications & Licensure

NE State Medical License 2003 - 2024
NY State Medical License 2000 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2013
QOPI Certification ASCO

Clinical Trials

A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Terminated
Phase 2
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Start of enrollment: 2011 Dec 01
Completed
Phase 2
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis Start of enrollment: 2014 Mar 01
Completed
Phase 2
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. Start of enrollment: 2015 May 01
Completed
Phase 2
Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer Start of enrollment: 2015 Jul 01
Completed
Phase 1
Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201 Start of enrollment: 2016 Sep 01
Completed
Phase 3
Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients Start of enrollment: 2016 Dec 01
Completed
Phase 1
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer Start of enrollment: 2018 Jun 19
Recruiting
Phase 3
Roles: Contact
INTREPId (INTermediate Risk Erection PreservatIon Trial) Start of enrollment: 2020 Jun 01
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
Neal D Shore, Maha Hussain, Fred Saad, Karim Fizazi, Cora N Sternberg, David Crawford, Bertrand Tombal, Michael Cookson, Frank Verholen, Jay Jhaveri, Shankar Srinivasa...> ;The Oncologist. 2024 Mar 4
2 citations
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic c...
Karen A Autio, Celestia S Higano, Luke Nordquist, Leonard J Appleman, Tian Zhang, Xin-Hua Zhu, Hani Babiker, Nicholas J Vogelzang, Sandip M Prasad, Michael T Schweizer...> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS study.
Neal D Shore, Felipe Cruz, Luke Nordquist, Laurence Belkoff, William J Aronson, Bhupendra Tolia, Arnold Cinman, Jorge Ortiz, Jacqueline Parkin, Shankar Srinivasan, Ton...> ;Future Oncology. 2022 Dec 1
1 citations
Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort ...
Evan Y Yu, Josep M Piulats, Gwenaelle Gravis, Peter C C Fong, Tilman Todenhöfer, Brigitte Laguerre, Jose A Arranz, Stephane Oudard, Christophe Massard, Julia Heinzelbe...> ;European Urology. 2023 Mar 1
19 citations
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
Evan Y Yu, Josep M Piulats, Gwenaelle Gravis, Peter C C Fong, Tilman Todenhöfer, Brigitte Laguerre, Jose A Arranz, Stephane Oudard, Christophe Massard, Julia Heinzelbe...> ;European Urology. 2023 Jan 1
3 citations
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prosta...
Karen A. Autio, Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, Susan F. Slovin, Elisabeth I. Heath,...> ;European Urology Open Science. 2021 Dec 1
13 citations
Lutetium-177–prostate-specific membrane antigen ligand following radium-223 treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clin...
Alton O. Sartor, Christian la Fougère, Markus Essler, Samer Ezziddin, Gero Kramer, Jörg Elllinger, Luke T. Nordquist, John Sylvester, Giovanni Paganelli, Avivit Peer, ...> ;Journal of Nuclear Medicine. 2021 Jun 24
750 citations
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Oliver Sartor, Johann S. de Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El-Haddad, Cha...> ;The New England Journal of Medicine. 2021 Jun 23
2 citations
A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichlori...
Daniel P. Petrylak, Ulka N. Vaishampayan, K.R. Patel, Celestia S. Higano, Costantine Albany, Nancy A. Dawson, B.A. Mehlhaff, David I. Quinn, L.T. Nordquist, Volker Wag...> ;ESMO Open. 2021 Apr 1
Reply to potential underestimation of cerebrovascular events in the PROVENGE registry for the observation, collection, and evaluation of experience data.
Celestia S. Higano, Andrew J. Armstrong, Oliver Sartor, Nicholas J. Vogelzang, Philip W. Kantoff, David G. McLeod, Christopher Michael Pieczonka, David F. Penson, Neal...> ;Cancer. 2020 Jun 15
11 citations
CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens.
Neal D. Shore, Matthew P. Morrow, Trevor McMullan, Kimberly A. Kraynyak, Albert Sylvester, Khamal Bhatt, Jocelyn Cheung, Jean D. Boyer, Li Liu, Brian Sacchetta, Samant...> ;Molecular Therapy. 2020 May 6
45 citations
Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer
Celestia S. Higano, Andrew J. Armstrong, A. Oliver Sartor, Nicholas J. Vogelzang, Philip W. Kantoff, David G. McLeod, Christopher Michael Pieczonka, David F. Penson, N...> ;Cancer. 2019 Dec 1
11 citations
Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metast...
Oliver Sartor, Daniel Heinrich, Neil Mariados, María José Méndez Vidal, Daniel Keizman, Camilla Thellenberg Karlsson, Avivit Peer, Giuseppe Procopio, Stephen Frank, Ka...> ;The Prostate. 2019 Oct 1
11 citations
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.
Shilpa Gupta, Luke T. Nordquist, Mark D. Fleming, William R. Berry, Jingsong Zhang, Sharon L. Ervin, Joel R. Eisner, Edwina Baskin-Bey, Neal D. Shore> ;Clinical Cancer Research. 2018 Nov 1
23 citations
eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer.
Neal D. Shore, Ronald F. Tutrone, Neil Mariados, Luke T. Nordquist, Bryan A. Mehlhaff, Karyn J. Steere, Stacey Harrelson> ;Clinical Genitourinary Cancer. 2017 Nov 1
21 citations
Re-treatment with radium-223: First experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metas...
Oliver Sartor, Daniel Heinrich, Neil Mariados, M. J.Méndez Vidal, Daniel Keizman, C. Thellenberg Karlsson, Avivit Peer, G. Procopio, Stephen Frank, Kalevi Pulkkanen, E...> ;Annals of Oncology. 2017 Oct 1
44 citations
Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion
Katherine S. Virgo, Ethan Basch, D. Andrew Loblaw, Thomas K. Oliver, R. Bryan Rumble, Michael A. Carducci, Luke T. Nordquist, Mary-Ellen Taplin, Eric Winquist, Eric A....> ;Journal of Clinical Oncology. 2017 Apr 25
37 citations
Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer
Ajjai Alva, Luke Nordquist, Stephanie Daignault, Saby George, Jorge Ramos, Costantine Albany, Sudhir Isharwal, Matthew McDonald, Gregory Campbell, Pongwut Danchaivijit...> ;The Prostate. 2017 Apr 1
55 citations
Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer
Bruce Montgomery, Mario A. Eisenberger, Matthew Rettig, Franklin Chu, Roberto Pili, J. Stephenson, Nicholas J. Vogelzang, Alan J. Koletsky, Luke T. Nordquist, William ...> ;Clinical Cancer Research. 2016 Mar 15
8 citations
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Can...
Rahul Aggarwal, Tomasz M. Beer, Vivian Weinberg, Celestia S. Higano, Mary-Ellen Taplin, Charles J. Ryan, Amy M. Lin, Joshi J. Alumkal, Julie N. Graff, Luke T. Nordquis...> ;Clinical Genitourinary Cancer. 2015 Jun 1
244 citations
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Christopher G. Azzoli, Sarah Temin, Timothy Aliff, Sherman Baker, Julie R. Brahmer, David H. Johnson, Janessa L. Laskin, Gregory A. Masters, Daniel T. Milton, Luke Nor...> ;Journal of Clinical Oncology. 2011 Oct 1
182 citations
Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer
Howard I. Scher, Xiaoyu Jia, Kim N. Chi, Ronald de Wit, William R. Berry, Peter Albers, Brian S. Henick, David M. Waterhouse, Dean Ruether, Peter Rosen, A. A. Meluch, ...> ;Journal of Clinical Oncology. 2011 Jun 1
Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Can...
Harzstark AL, Beer TM, Weinberg VK, Higano CS, Nordquist LT, Rosenberg JE, Alumkal JJ, Yu EY, Mi J, Small EJ> ;J. Clin. Oncol.. 2011-03-01
11 citations
[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].
Christopher G. Azzoli, Sherman Baker, Sarah Temin, William Pao, Timothy Aliff, Julie R. Brahmer, David H. Johnson, Janessa L. Laskin, Gregory A. Masters, Daniel T. Mil...> ;Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer. 2010 Mar 1
810 citations
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Christopher G. Azzoli, Sherman Baker, Sarah Temin, William Pao, Timothy Aliff, Julie R. Brahmer, David H. Johnson, Janessa L. Laskin, Gregory A. Masters, Daniel T. Mil...> ;Journal of Clinical Oncology. 2009 Dec 20
Join now to see all

Journal Articles

Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer
Mark T Fleming, Luke T Nordquist, William R Berry, Clinical Cancer Research

Press Mentions

Clarity Completes First Stage of Prostate Cancer TrialMay 25th, 2023
Clarity's Theranostic Prostate Cancer Trial Advances to Cohort 2May 24th, 2023
First Patient Treated in Clarity's Therapeutic Prostate Cancer TrialOctober 7th, 2022
Join now to see all